Ken Griffin Uni Qure N.V. Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Uni Qure N.V. stock. As of the latest transaction made, Citadel Advisors LLC holds 60,900 shares of QURE stock, worth $352,002. This represents 0.0% of its overall portfolio holdings.

Number of Shares

60,900

Previous 65,200 6.6%

Holding current value

$352,002

Previous $292,000 2.74%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$3.78 - $10.12 $2.62 Million - $7.01 Million	-692,548 Reduced 85.6%	116,460 $574,000
Q2 2024 Aug 14, 2024	BUY	$4.39 - $5.43 $1.13 Million - $1.4 Million	258,441 Added 46.94%	809,008 $3.62 Million
Q1 2024 May 15, 2024	BUY	$4.82 - $6.93 $1.83 Million - $2.63 Million	379,523 Added 221.89%	550,567 $2.86 Million
Q4 2023 Feb 14, 2024	SELL	$5.63 - $8.27 $2.09 Million - $3.07 Million	-370,868 Reduced 68.44%	171,044 $1.16 Million
Q3 2023 Nov 14, 2023	SELL	$6.71 - $11.83 $766,456 - $1.35 Million	-114,226 Reduced 17.41%	541,912 $3.64 Million
Q2 2023 Aug 14, 2023	BUY	$11.12 - $22.2 $3.49 Million - $6.97 Million	313,773 Added 91.65%	656,138 $7.52 Million
Q1 2023 May 15, 2023	BUY	$18.7 - $23.07 $2.59 Million - $3.19 Million	138,318 Added 67.79%	342,365 $6.9 Million
Q4 2022 Feb 14, 2023	BUY	$18.12 - $27.32 $21,091 - $31,800	1,164 Added 0.57%	204,047 $4.63 Million
Q3 2022 Nov 14, 2022	SELL	$16.98 - $25.54 $612,774 - $921,687	-36,088 Reduced 15.1%	202,883 $3.81 Million
Q2 2022 Aug 15, 2022	BUY	$13.15 - $20.45 $2.57 Million - $3.99 Million	195,237 Added 446.42%	238,971 $4.45 Million
Q1 2022 May 16, 2022	BUY	$14.54 - $21.5 $137,054 - $202,659	9,426 Added 27.47%	43,734 $790,000
Q4 2021 Feb 14, 2022	BUY	$20.24 - $36.01 $417,186 - $742,238	20,612 Added 150.5%	34,308 $711,000
Q3 2021 Nov 15, 2021	SELL	$26.01 - $38.22 $34.1 Million - $50.1 Million	-1,310,603 Reduced 98.97%	13,696 $438,000
Q2 2021 Aug 16, 2021	BUY	$29.97 - $37.17 $809,279 - $1 Million	27,003 Added 2.08%	1,324,299 $40.8 Million
Q1 2021 May 17, 2021	BUY	$29.24 - $42.03 $26 Million - $37.4 Million	888,660 Added 217.47%	1,297,296 $43.7 Million
Q4 2020 Feb 16, 2021	SELL	$35.35 - $50.67 $498,470 - $714,497	-14,101 Reduced 3.34%	408,636 $14.8 Million
Q3 2020 Nov 16, 2020	BUY	$35.98 - $47.66 $4.09 Million - $5.42 Million	113,792 Added 36.83%	422,737 $15.6 Million
Q2 2020 Aug 14, 2020	BUY	$45.06 - $67.74 $11 Million - $16.6 Million	244,817 Added 381.76%	308,945 $13.9 Million
Q1 2020 May 15, 2020	SELL	$40.01 - $73.97 $13.8 Million - $25.4 Million	-343,927 Reduced 84.28%	64,128 $3.04 Million
Q4 2019 Feb 14, 2020	BUY	$37.13 - $74.62 $4.03 Million - $8.1 Million	108,513 Added 36.23%	408,055 $29.2 Million
Q3 2019 Nov 14, 2019	SELL	$39.36 - $76.8 $353,413 - $689,587	-8,979 Reduced 2.91%	299,542 $11.8 Million
Q2 2019 Aug 14, 2019	BUY	$52.76 - $82.19 $11 Million - $17.1 Million	208,187 Added 207.49%	308,521 $24.1 Million
Q1 2019 May 15, 2019	SELL	$27.39 - $68.41 $5.84 Million - $14.6 Million	-213,362 Reduced 68.02%	100,334 $0
Q4 2018 Feb 14, 2019	BUY	$22.8 - $33.93 $4.72 Million - $7.03 Million	207,163 Added 194.46%	313,696 $9.04 Million
Q3 2018 Nov 13, 2018	SELL	$29.75 - $43.08 $1.09 Million - $1.58 Million	-36,585 Reduced 25.56%	106,533 $0
Q2 2018 Aug 10, 2018	SELL	$21.96 - $39.94 $3.46 Million - $6.29 Million	-157,567 Reduced 52.4%	143,118 $0
Q1 2018 May 11, 2018	BUY	$17.1 - $26.61 $4.78 Million - $7.44 Million	279,468 Added 1317.19%	300,685 $7.07 Million
Q4 2017 Feb 09, 2018	BUY	$9.47 - $19.59 $200,924 - $415,641	21,217	21,217 $416,000

Others Institutions Holding QURE

# of Institutions

153

Shares Held

41M

Call Options Held

925K

Put Options Held

617K

View Full List

About uniQure N.V.

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $270M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

More about QURE

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account